Advertisement

Specialty News

November 28, 2017
November 28, 2017
Approximately 94% of hepatitis C patients who were prescribed direct-acting antiretrovirals (DAAs) were able to achieve the primary outcome goal,...
Approximately 94% of hepatitis C patients who were prescribed direct-acting antiretrovirals (DAAs) were able to achieve the primary outcome goal, sustained virologic response (SVR), even though many patients had advanced liver disease, previous treatment failure, or previous liver transplants, according to a recent Walgreens Center for Health and W
MORE
November 27, 2017
November 27, 2017
First and only two-dose vaccine for hepatitis B approved
MORE
November 28, 2017
November 27, 2017
Small startup Tremeau Pharmaceuticals is engineering a comeback of Vioxx, which at one time delivered pain relief to millions of people with...
Small startup Tremeau Pharmaceuticals is engineering a comeback of Vioxx, which at one time delivered pain relief to millions of people with arthritis or other chronic pain. The former Merck & Co.
MORE
November 22, 2017
November 22, 2017
FDA on Tuesday approved dolutegravir + rilpivirine (Juluca—ViiV Healthcare), the first complete treatment regimen containing only two drugs to treat...
FDA on Tuesday approved dolutegravir + rilpivirine (Juluca—ViiV Healthcare), the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment.
MORE
November 22, 2017
November 22, 2017
NIH and Stanford University researchers designed a Phase I study to evaluate a new treatment for relapsed and/or refractory pre-B cell acute...
NIH and Stanford University researchers designed a Phase I study to evaluate a new treatment for relapsed and/or refractory pre-B cell acute lymphoblastic leukemia (B-ALL). Current practice relies on the use of chimeric antigen receptor (CAR) T cells that target CD19; however, antigen loss often prevents this approach from being effective.
MORE
November 22, 2017
November 22, 2017
The purpose of the FLAURA study was to compare epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in treating advanced non-...
The purpose of the FLAURA study was to compare epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in treating advanced non-small-cell lung cancer patients with an EGFR mutation.
MORE
November 20, 2017
November 20, 2017
A new report from UNAIDS points to the increase in HIV treatment access and highlights the right to health as the key to ending AIDS. According to...
A new <a href="http://www.unaids.org/en/resources/documents/2017/20171120_right_to_health" target="_blank">report</a> from UNAIDS points to the increase in HIV treatment access and highlights the right to health as the key to ending AIDS.
MORE
November 20, 2017
November 20, 2017
FDA on Thursday approved sunitinib malate (Sutent—Pfizer) for the adjuvant treatment of adult patients who are at a high risk of renal cell...
FDA on Thursday approved sunitinib malate (Sutent&#8212;Pfizer) for the adjuvant treatment of adult patients who are at a high risk of renal cell carcinoma returning after a kidney has been removed. Adjuvant treatment is a form of therapy that is taken after an initial surgical removal to lower the risk of the cancer coming back.
MORE
November 01, 2017
November 01, 2017
FDA on Tuesday granted accelerated approval to acalabrutinib (Calquence—AstraZeneca) for the treatment of adults with mantle cell lymphoma who have...
FDA on Tuesday granted accelerated approval to acalabrutinib (Calquence&#8212;AstraZeneca) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.
MORE
November 01, 2017
November 01, 2017
Colleagues at the France-based International Agency for Research on Cancer conducted a study to characterize the global burden of cancer on patients...
Colleagues at the France-based International Agency for Research on Cancer conducted a study to characterize the global burden of cancer on patients aged 20&#8211;39 years. Using 2012 data, they identified 975,396 new cancer cases in this demographic that year&#8212;along with 358,392 related deaths.
MORE

Pages